XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $483K invested in XTL Biopharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $378K → $483K (+$105K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
+$6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$506 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Invesco
Atlanta,
Georgia
| $473K | – | – | – |
|
|
U
2
UBS
Zurich,
Switzerland
| $6K | +$6K | +83 | New |
|
3
Ameriprise
Minneapolis,
Minnesota
| $2K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | +$506 | +7 | +39% |
|
XTLB Hedge Fund Activity: Q1 2014 in Review
4 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2014, worth a combined $483K — up 28% from $378K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS, opening a new position worth an estimated $6K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2014, up from 3 in Q4 2013.
- Funds reported $483K of XTL Biopharmaceuticals stock for Q1 2014, up 28% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q1 2014 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q1 2014 was UBS, an estimated $6K added.
Based on aggregated 13F filings for Q1 2014.